Conavi Medical Corp., a medical device company specializing in cardiovascular imaging technologies, announced it has granted 1.6 million stock options to its officers. These options are exercisable at C$0.20 per share and vest over four years, with a ten-year term. The grant is subject to approval by the TSX Venture Exchange. This move aligns with Conavi's strategy to incentivize management as it advances commercialization of its hybrid imaging system for minimally invasive cardiovascular procedures.
Conavi Medical's announcement of 1.6 million stock options grants comes as a backdrop to a broadly positive health sector on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 20, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 84 rose and 65 fell. Notable movers include Summit Therapeutics Inc (SMMT) at USD 15.53 with a 6.15% increase, Twist Bioscience Corp (TWST) at USD 140.34 up 5.72%, and SELLAS Life Sciences Group Inc. (SLS) at USD 10.50 rising 5.21%.
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
